Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Short term Debt (2022)

Denali Therapeutics has reported Short term Debt over the past 1 years, most recently at $4.4 million for Q4 2022.

  • Quarterly Short term Debt changed N/A to $4.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2022, changed N/A year-over-year, with the annual reading at $4.4 million for FY2022, N/A changed from the prior year.
  • Short term Debt was $4.4 million for Q4 2022 at Denali Therapeutics, up from $1.4 million in the prior quarter.
  • Over five years, Short term Debt peaked at $4.4 million in Q4 2022 and troughed at $1.4 million in Q3 2022.